One of the major specific challenges in childhood cancer is Group 3 medulloblastoma driven by the over-abundance of a gene called MYC (MYC-MBGroup3). This tumour group occurs almost exclusively in young children and is essentially incurable, contributing significantly to overall childhood cancer death rates. New targeted treatments are urgently needed to improve the outlook for children with high-risk medulloblastoma. The INSTINCT-MB project will seek to develop new treatments for MYC-MBGroup3, using new drugs and promising new immunotherapies known as Chimeric Antigen Receptor T-cells (CAR-T) therapies.
INSTINCT-MB: Strategic implementation of novel combination therapeutics for high-risk medulloblastoma
Professor Steve Clifford
Newcastle University Centre for Cancer, Newcastle University
Newcastle upon Tyne, NE1 7RU
1 February 2022
£712,027 co-funded by Blue Skye Thinking and Little Hero